Written Presentation to FDA September 12, 2017

On September 12, 2017, Ceciel Rooker presented the following research information to the US Food and Drug Administration (FDA) concerning the burdens and needs of gastroparesis patients: On behalf of the International Foundation for Functional Gastrointestinal Disorders (IFFGD), we appreciate the opportunity provided by the FDA to hear the patient perspective at the Patient-Focused Drug […]

Oral Comments to FDA May 11, 2015

On May 11, 2015, Tegan Gaetano took part in and presented the following comments on behalf of IFFGD members at the FDA Patient-Focused Drug Development public meeting on Functional GI Disorders: Good afternoon. My name is Tegan Gaetano. I work for a patient advocacy organization, the International Foundation for Functional Gastrointestinal Disorders, or IFFGD. I […]

FISCAL YEAR 2016

IFFGD Founder and President, Nancy Norton, submitted the following written statement to the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies regarding Fiscal Year (FY) 2016 appropriations for the National Institutes of Health (NIH) on April 29, 2015: STATEMENT OF NANCY J. NORTON PRESIDENT AND CO-FOUNDERINTERNATIONAL FOUNDATION FOR FUNCTIONAL GASTROINTESTINAL […]

Written Comments to Noridian October 24, 2013

IFFGD Vice President, William Norton, submitted the following written comments to Noridian Administrative Services in response to the decision by Noridian to deny Medicare coverage for the Solesta procedure for the treatment of fecal incontinence in adults who fail conservative therapy. On behalf of the International Foundation for Functional Gastrointestinal Disorders (IFFGD) I am writing […]

Testimony to FDA October 25, 2012

IFFGD President and Co-Founder, Nancy J. Norton submitted the following written statement on October 25, 2012 to the Food and Drug Administration Division of Dockets Management in response to docket number: FDA-2012-N-0967, the Prescription Drug User Fee Act Patient-Focused Drug Development Meeting: Thank you for the opportunity to present the views of the International Foundation […]

Testimony to FDA September 12, 2012

IFFGD Vice-President, William Norton, submitted the following written public testimony to the FDA in connection with an October 16, 2012 meeting of the Gastrointestinal Drugs Advisory Committee to consider the new drug application (NDA) 203441 by NPS Pharmaceuticals for the drug with the proposed trade name GATTEX® (teduglutide) for the treatment of adult patients with […]

Testimony to FDA December 13, 2011

IFFGD Vice-President, William Norton, submitted the following written public testimony to the FDA in connection with a January 11, 2012 meeting of the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee to consider the premarket approval of the LINX Reflux Management System for the treatment of gastroesophageal reflux disease (GERD): On behalf […]

Testimony to FDA December 2, 2010

On December 2, 2010, Dane Christiansen provided the following testimony on behalf of IFFGD members to the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee regarding the consideration of the Ocean Theapeutics’ product Solesta for the treatment of incontinence: Good afternoon. My name is Dane Christiansen and I am here today representing […]

FISCAL YEAR 2010

IFFGD Founder and President, Nancy Norton, submitted the following written statement to the House Committee on Appropriations; Subcommittee on Labor, Health and Human Services, Education and Related Agencies regarding Fiscal Year 2010 appropriations for the National Institutes of Health on May 1, 2009: Thank you for the opportunity to present this written statement regarding the […]

FISCAL YEAR 2009

Nancy J. Norton, President and Co-Founder of IFFGD submitted the following written statement regarding Fiscal Year 2009 appropriations for the National Institutes of Health to the Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies on April 28, 2008: Thank you for the opportunity to present this written statement […]

FISCAL YEAR 2007

On May 19, 2006, Nancy J. Norton, President and Founder of IFFGD presented the following testimony regarding Fiscal Year 2007 Funding for Functional Gastrointestinal and Motility Disorders Research before both the U.S. Senate and U.S. House Appropriations Subcommittees on Labor, Health & Human Services, Education and Related Agencies: Mr. Chairman and members of the Subcommittee, […]

FISCAL YEAR 2006

Nancy J. Norton, President and Founder of IFFGD presented the following testimony regarding Fiscal Year 2006 Funding for Functional Gastrointestinal and Motility Disorders Research before the House Appropriations Subcommittee on Labor, Health & Human Services, Education and Related Agencies in 2005: Chairman Regula and members of the Subcommittee, thank you for the opportunity to present […]